48,466
edits
Difference between revisions of "Lung carcinoma with EGFR mutation"
Jump to navigation
Jump to search
Lung carcinoma with EGFR mutation (view source)
Revision as of 02:19, 31 December 2019
, 02:19, 31 December 2019→See also
m (Michael moved page Lung adenocarcinoma with EGFR rearrangement to Lung carcinoma with EGFR rearrangement) |
|||
| (11 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Lung | '''Lung carcinoma with EGFR mutation''' is a molecular subtype of [[lung carcinoma]]. Morphologically, these tumours are typically [[adenocarcinoma]]s. | ||
==General== | |||
*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | |||
**Testing done together with ALK. | |||
*EGRF mutation excludes [[Lung carcinoma with ALK rearrangement|ALK rearrangement]].<ref name=pmid23729361>{{Cite journal | last1 = Gainor | first1 = JF. | last2 = Varghese | first2 = AM. | last3 = Ou | first3 = SH. | last4 = Kabraji | first4 = S. | last5 = Awad | first5 = MM. | last6 = Katayama | first6 = R. | last7 = Pawlak | first7 = A. | last8 = Mino-Kenudson | first8 = M. | last9 = Yeap | first9 = BY. | title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. | journal = Clin Cancer Res | volume = 19 | issue = 15 | pages = 4273-81 | month = Aug | year = 2013 | doi = 10.1158/1078-0432.CCR-13-0318 | PMID = 23729361 }}</ref> | |||
Treatement:<ref name=pmid20887192>{{Cite journal | last1 = da Cunha Santos | first1 = G. | last2 = Shepherd | first2 = FA. | last3 = Tsao | first3 = MS. | title = EGFR mutations and lung cancer. | journal = Annu Rev Pathol | volume = 6 | issue = | pages = 49-69 | month = | year = 2011 | doi = 10.1146/annurev-pathol-011110-130206 | PMID = 20887192 }}</ref> | |||
*[[Tyrosine kinase inhibitors]]. | |||
===Associations=== | |||
Varies significantly by population:<ref name=pmid27738317>{{Cite journal | last1 = Zhang | first1 = YL. | last2 = Yuan | first2 = JQ. | last3 = Wang | first3 = KF. | last4 = Fu | first4 = XH. | last5 = Han | first5 = XR. | last6 = Threapleton | first6 = D. | last7 = Yang | first7 = ZY. | last8 = Mao | first8 = C. | last9 = Tang | first9 = JL. | title = The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. | journal = Oncotarget | volume = 7 | issue = 48 | pages = 78985-78993 | month = Nov | year = 2016 | doi = 10.18632/oncotarget.12587 | PMID = 27738317 }}</ref> | |||
{| class="wikitable sortable" | |||
! Population | |||
! Prevalence | |||
! Category | |||
|- | |||
| Europe | |||
| 14% | |||
| Geographic | |||
|- | |||
| China | |||
| 38% | |||
| Geographic | |||
|- | |||
| Females | |||
| 44% | |||
| Patient characteristics | |||
|- | |||
| Males | |||
| 24% | |||
| Patient characteristics | |||
|- | |||
| Non-smokers | |||
| 49% | |||
| Patient characteristics | |||
|- | |||
| Smokers or past smokers | |||
| 22% | |||
| Patient characteristics | |||
|- | |||
| Adenocarcinoma | |||
| 38% | |||
| Pathology | |||
|- | |||
| Non-adenocarcinoma | |||
| 12% | |||
| Pathology | |||
|} | |||
==Sign out== | ==Sign out== | ||
| Line 8: | Line 56: | ||
==See also== | ==See also== | ||
*[[Lung | *[[Lung carcinoma with ALK rearrangement]]. | ||
*[[Epidermal growth factor receptor inhibitors]]. | |||
*[[ROS1-rearranged non-small cell lung carcinoma]]. | |||
==References== | ==References== | ||